American health authorities have initiated the process to lift the black box warning from estrogen-based medications used to manage menopausal symptoms.
This warning was initially instituted following findings from a significant government-sponsored women’s health investigation, the Women’s Health Initiative (WHI), which indicated a correlation between hormone therapy and elevated risks for various ailments, such as breast cancer, cardiovascular disease, blood clots, and potential dementia.
According to specialists in women’s health, these risks were misunderstood and did not accurately represent the study’s data. Consequently, in subsequent years, numerous women and their physicians refrained from using hormone therapy for menopausal symptoms like hot flashes, nocturnal sweats, and mood fluctuations.
Dr. Marty Makary, the commissioner of the U.S. Food and Drug Administration (FDA), stated that the agency gathered an expert panel in July to assess the warning label and offer recommendations. The FDA’s in-house subject matter specialists then evaluated these expert insights and resolved to eliminate the black box warning. Manufacturers of estrogen products are now required to update their product labels.
Numerous women’s health specialists have for a considerable time advocated for the removal of the black box warning, particularly concerning specific estrogen formulations. Vaginal estrogen products, prescribed for post-menopausal vaginal dryness that can heighten the risk of urinary tract infections, are administered topically, and urologists have consistently argued that the risks detailed in the black box warning were less relevant to these particular forms.
“On a global scale, I would contend that rescinding the black box warning from the label is considerably overdue,” commented Dr. Kathleen Jordan, chief medical officer at Midi Health, a virtual healthcare provider assisting 20,000 midlife women weekly. “Specialists concur that it exaggerates the risks associated with estrogen, particularly for low-dose vaginal estrogen, which demonstrates negligible systemic absorption and very few, if any, associated risks.”
The American College of Obstetrics and Gynecology (ACOG) experts indicate that alternative types of hormone therapy, including patches or pills, result in varied systemic exposures, thus presenting distinct risk profiles. Consequently, the discussion regarding risks versus benefits for these methods ought to differ.
“ACOG’s guidelines remain unaltered by the black box warning’s removal,” stated Dr. Stella Dantas, immediate past president of ACOG and an obstetrician-gynecologist with Northwest Kaiser Permanente. The organization continues to advise women aged 50 to 59 experiencing menopausal symptoms like hot flashes, night sweats, vaginal dryness, or sleep disturbances, to consult their doctor about the suitability of hormone therapy.
This dialogue should encompass an assessment of a woman’s family and individual history concerning breast cancer and other health considerations. “We recognize that hormone therapy can significantly aid and benefit women in managing symptoms,” Dantas explained. “Nevertheless, the advice we provide and the collaborative decision-making process regarding whether benefits exceed risks also hinge on a woman’s personal and family medical background.”
Modern hormone therapy for women diverges significantly from the treatment examined in the WHI. During the WHI, participants were given oral estrogen and synthetic progestin, whereas currently, most physicians initiate treatment with an estrogen patch and employ a form of progesterone that more closely mirrors the body’s natural hormone and is considered more “breast neutral,” Jordan noted.
Dantas remarked that the demographic of women involved in the WHI study also varied considerably from those typically receiving hormone treatments nowadays. The WHI comprised women who were generally older, having passed menopause by approximately a decade. “They were not being treated for menopausal symptoms and were post-menopause, meaning the adverse effects of declining estrogen levels on their arteries and other bodily systems had already commenced,” she elaborated. “In contrast, our current focus is on treating women for menopausal symptoms using medications that exhibit different risk profiles.”
Dantas, nonetheless, highlighted that the administration method of hormone therapy—whether by pill or patch—is crucial, as it can result in varying levels of bodily exposure and associated risk. While the majority of specialists concur that vaginal estrogen does not necessitate the black box warning—the FDA’s most stringent caution—oral and patch forms of estrogen are formulated to disseminate more broadly throughout the body, thereby presenting a distinct degree of risk.
“My wish list would certainly include a more extensive review to reassess the appropriate labeling for systemic estrogen therapy,” she mentioned. “I believe removing the black box warning from vaginal creams and rings differs from its removal for more systemic therapies, such as oral estrogen, given their distinct risk profiles, which are currently being blurred. I feel that sufficient data now exists to extrapolate and demonstrate any differences between the transdermal patch and vaginal estrogen, which would help determine the most suitable warning for patients.”
Specialists further warn that the benefits of hormone therapy, beyond alleviating menopausal symptoms, remain undefined. Makary observed that hormone therapy might assist women in managing several other health issues linked to post-menopause, such as heart disease and osteoporosis. “Presently, there are significant long-term health advantages that few individuals, including doctors, are aware of,” he stated. “With rare exceptions, perhaps no other contemporary medication enhances women’s health outcomes at a population level as effectively as hormone therapy.”
Although encouraging data indicates that women on hormone therapy might lower their risk of bone fractures and heart disease, particularly, the evidence is not strong enough for hormones to be the main approach for these health concerns. “Other medications exist for osteoporosis, and others to manage cholesterol,” Dantas clarified. “Hormone therapy ought not to be the principal treatment for other illnesses or conditions. Its true purpose is to alleviate menopause symptoms.”
While a positive move towards better educating women on the risks and benefits of hormone therapy, the lifting of the black box warning should not be misconstrued as implying that these treatments are without risk. Furthermore, Dantas advises that women should not presume all hormone therapy forms are identical. She urges women encountering menopausal symptoms to engage in discussions with their physicians regarding how hormone therapy could benefit them and what specific potential risks they might face.
